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In 2015–2016, a Zika virus (ZIKV) outbreak occurred in 
the Americas. In 2017, we conducted a ZIKV serosurvey in 
Suriname in which 770 participants were recruited from 1 
urban area and 2 rural villages in the tropical rainforest. All 
collected samples were tested for presence of ZIKV antibodies 
using a ZIKV immunoglobulin G enzyme-linked immuno-
sorbent assay and a virus neutralization assay. We found that 
35.1% of the participants had neutralizing antibodies against 
ZIKV. In 1 remote village in the rainforest, 24.5% of the partici-
pants had neutralizing antibodies against ZIKV, suggesting that 
ZIKV was widely spread across Suriname.
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In 2015–2016, an outbreak of the arthropod-borne flavivirus, 
Zika virus (ZIKV), occurred in the Americas. This was the first 
time ZIKV was detected in this region [1, 2]. Early in this out-
break, it became clear that a ZIKV infection can have severe 
complications such as Guillain-Barré syndrome and congenital 
malformations in offspring of mothers who were infected with 
ZIKV during pregnancy [3]. In many areas, ZIKV circulation 
decreased rapidly after the initial wave of infections [4, 5]. The 
quick decline of ZIKV circulation in these regions can have 
multiple causes, one of which is rapid development of popula-
tion immunity due to a high number of infections during the 
peak of the outbreak.
Following the first ZIKV outbreaks in other regions, ZIKV 
seroprevalence studies performed in Micronesia in 2009 and 
French Polynesia in 2014–2015 reported a seroprevalence of 
73% and 49%, respectively [6, 7]. However, these studies did 
not use a virus neutralization assay, which is of importance for 
flavivirus serology as recent studies have shown that, in samples 
from dengue virus (DENV)–endemic areas, commonly used 
nonstructural protein 1 (NS1)–based ZIKV antibody enzyme-
linked immunosorbent assays (ELISAs) can give a high amount 
of false-positive results due to cross-reactivity with other flavi-
virus antibodies [8–10]. Although cross-neutralization can also 
be observed when using a viral neutralization assay, this assay 
measures functional antibodies that are capable of blocking 
ZIKV infection of cells, and therefore is a better measure of im-
munity than binding antibodies detected by most ELISAs [11]. 
Three ZIKV seroprevalence studies using a micro–virus neu-
tralization test (VNT) or plaque reduction neutralization test 
were recently performed in the Americas and reported a ZIKV 
seroprevalence ranging from 0% in the highlands of Bolivia to 
63.3% in Salvador, Brazil [8, 10, 12]. More knowledge about 
the level of population immunity to ZIKV is important for risk 
estimation of future ZIKV outbreaks in these areas and to de-
termine whether implementation of a ZIKV vaccine would be 
beneficial in increasing the population immunity rate for ZIKV. 
In this study, we collected samples from Surinamese inhabi-
tants in the capital, Paramaribo, and in 2 remote villages in the 
tropical rainforest of Suriname to assess the spread of ZIKV in 
these areas.
METHODS
Study Ethics
This study was approved by the national medical ethical board 
of Suriname. Informed consent was signed after provision of 
information on paper or verbally in the local language with the 
help of local health workers.
Study Population
Participants were recruited from 3 different locations in 
Suriname (Supplementary Figure 1) in January and February 
2017, which was 1 year after the peak of the ZIKV outbreak in 
Suriname when there was almost no reported ZIKV circulation 
in Suriname [13]. In the capital of Suriname, Paramaribo, re-
cruitment was performed at the emergency department of the 
Academic Hospital Paramaribo to ensure an even distribution 
of the area of residence in Paramaribo as it is the only emer-
gency department in town. All patients visiting the emergency 
department were asked to participate in this study except those 
who were marked with triage code 1 (life threatening) and 
those who were not living in Suriname for at least 2 years. The 
second location from where participants were recruited was at 
the healthcare center of Laduani where a Maroon community 
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of around 1300 persons lives in the rainforest. Last, partic-
ipants were recruited in Kwamalasamutu, a very remote Trio 
Amerindian community consisting of around 1100 persons, 
located in the rainforest near the Brazilian border. In both 
Laduani and Kwamalasamutu, 1 member of all households was 
asked for participation in this study to ensure an even distribu-
tion of residence area of the participants in the villages.
To test the serological cross-reactivity of the different diag-
nostic tests used in this study, 44 serum samples from patients 
with fever, which were sent to the Bureau of Public Health in 
Suriname, were also tested. These samples, henceforth called 
the pre-ZIKV cohort, were collected between 2012 and the be-
ginning of 2014, well before ZIKV was reported to circulate in 
Suriname [1, 2, 13].
Sample and Data Collection
Blood samples were collected from each participant via ven-
ipuncture. Participants in Paramaribo were asked to fill out a 
short questionnaire asking about their yellow fever virus (YFV) 
vaccination status and if they had experienced any clinical symp-
toms of a ZIKV infection (eg, skin rash, arthralgia, conjuncti-
vitis, fever) in the past 2 years. Because of a language barrier, this 
questionnaire was not conducted in the 2 inland villages.
Serological Assays
At least 30 minutes after collection, blood samples were cen-
trifuged at 3500  rpm for 8 minutes and serum was stored at 
–20°C upon shipment to the Netherlands for analysis in the 
World Health Organization (WHO) Collaborating Centre for 
Arbovirus and Haemorrhagic Fever Reference and Research at 
Erasmus Medical Centre in Rotterdam, the Netherlands. The 44 
samples of the pre-ZIKV cohort were tested with a DENV-2 virus 
particle-based commercial DENV ELISA kit (Euroimmun) ac-
cording to the manufacturer’s instructions. For ZIKV immuno-
globulin G (IgG) antibody detection, all of the collected samples 
were tested with a commercial NS1-based ZIKV IgG ELISA kit 
(Euroimmun) according to the manufacturer’s instructions. All 
of the collected samples were also tested with a ZIKV VNT. For 
the VNT, 2-fold dilutions of serum were incubated with 100 50% 
Tissue culture Infective Dose (TCID50) of ZIKV Suriname strain 
2016 (GenBank reference KU937936, EVAg Ref-SKU: 011V-
01621) and transferred to a confluent monolayer of Vero cells. 
After 1 hour of incubation, the serum-virus mix was removed 
from the Vero cells, 2% fetal calf serum containing Dulbecco’s 
modified Eagle’s medium was added and plates were incubated 
for 5 days at 37°C and 5% carbon dioxide. Readout of the VNT 
was done through cytopathogenic effect (CPE) detection via 
light microscopy. Samples were tested in triplicate and the geo-
metric mean of the highest final serum dilution that completely 
prevented infection (ie, no CPE) was calculated per sample and 
reported as reciprocal titer. For quality control, a standard pos-
itive and negative control serum was included for each VNT 
run. The cutoff for a positive ZIKV VNT result was set at a 
final serum dilution >1:32 according to the results from an in-
ternal validation process at the WHO Collaborating Centre for 
Arbovirus and Haemorrhagic Fever Reference and Research at 
Erasmus Medical Centre, in which sera from confirmed ZIKV-
infected patients were compared with sera that were seropositive 
for other flaviviruses such as DENV, YFV, and West Nile virus.
Statistical Analysis
Correlations between age and ZIKV VNT titers were analyzed 
using Spearman correlation analysis. The Mann–Whitney U 
test was used to compare ZIKV VNT titers between sexes and 
sampling locations. Pearson χ2 test was used to compare VNT 
seroprevalence between the 3 different sampling locations, 
sexes, participants with or without reported ZIKV symptoms, 
and YFV-vaccinated and -unvaccinated participants. All sta-
tistical analyses were performed with IBM SPSS for Windows, 
version 24. A P value < .05 was considered to be a statistically 
significant difference.
RESULTS
In total, the 2017 cohort consisted of 770 participants with a 
mean age of 44.8  years (standard deviation, 17.8  years). The 
pre-ZIKV cohort consisted of samples from 44 patients from 
Suriname that were collected between 2012 and 2014. All sam-
ples were tested with both the ZIKV IgG ELISA and ZIKV VNT 
(see Supplementary Table 1 for comparison of results). In the 
pre-ZIKV cohort, 39 samples (88.6%) tested positive for DENV 
IgG with ELISA. In this cohort, 23 samples (52.3%) tested posi-
tive for ZIKV IgG with ELISA, whereas none of the 44 pre-ZIKV 
samples tested positive with the ZIKV VNT (Table 1). In the 2017 
cohort, 530 samples (68.8%) tested positive for ZIKV IgG with 
ELISA, whereas 270 (35.1%) samples tested positive with ZIKV 
VNT. The ZIKV VNT seroprevalence was comparable between 
Paramaribo and Laduani (38.2% vs 36.7%; P = .71), but signifi-
cantly lower in the remote village Kwamalasamutu compared to 
Paramaribo (24.5% vs 38.2%; P = .002). ZIKV VNT titers were 
comparable between Paramaribo and Laduani (median titer, 20 
vs 26; P = .72) but were significantly higher in Paramaribo com-
pared to Kwamalasamutu (median titer, 20 vs 0; P <  .001). All 
the tested ZIKV VNT titers are represented in Figure 1. There 
was no difference in ZIKV VNT seroprevalence between the dif-
ferent age groups (Table 1; P = .49). Additionally, there was no 
correlation between age and ZIKV VNT titer (Spearman corre-
lation, r = 0.02; P = .52). The seroprevalence of ZIKV neutraliz-
ing antibodies did not differ between males and females (33.8% 
vs 36.0%; P =  .51), nor did the ZIKV VNT titer (median titer, 
16 vs 16; P =  .77). ZIKV VNT seroprevalence between partic-
ipants who reported 1 or more symptoms of ZIKV infection in 
the past 2 years did not differ compared to asymptomatic par-
ticipants (34.6% vs 40.4%; P = .24). Last, the ZIKV VNT sero-
prevalence did also not differ between participants reported to 
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be vaccinated against YFV and participants who were not YFV 
vaccinated or did not know if they were YFV vaccinated (41.6% 
vs 36.0% vs 36.1%; P = .43). Assuming that participants from the 
pre-ZIKV cohort were indeed ZIKV naive, as there was no ZIKV 
circulating in the Americas at the time of sampling, the speci-
ficity of the ZIKV IgG ELISA was 47.7% (21/44).
DISCUSSION
Our study found that approximately one-third of the recruited 
persons in the 2017 cohort had neutralizing antibodies against 
ZIKV and thus evidence for a previous ZIKV infection. These 
results are similar to previously performed seroprevalence 
studies in the Americas that demonstrated a prevalence of 
ZIKV neutralizing antibodies of 21.5%–33% in tropical areas in 
Bolivia and 42.2% in Martinique, but lower than the seroprev-
alence observed in Salvador, Brazil (66.2%) [8, 10, 12]. Even in 
the very remote village Kwamalasamutu, the seroprevalence of 
neutralizing ZIKV antibodies was still 24.5%. This indicates that 
ZIKV was widely spread across Suriname, not only in urban 
areas but also in rural areas. The observation that two-thirds 
of the population was seronegative suggests that implementa-
tion of a ZIKV vaccine, when available, might be worthwhile in 
these regions.
All of the samples of the 2017 cohort were tested with the 
ZIKV VNT and a ZIKV IgG ELISA; 270 samples tested posi-
tive with the ZIKV VNT while, interestingly, with ELISA, 530 
Table 1. ZIKV IgG ELISA and VNT results in 2017 cohort and pre-ZIKV cohort
Participants  
(% of total)
Positive ZIKV IgG ELISA  
result, No. (% [95% CI])
Positive VNT result,  
No. (% [95% CI])
2017 Cohort  
Total cohort 770 (100) 530 (68.8 [65.5–72.0]) 270 (35.1 [31.8–38.5])
 Paramaribo 424 (55.1) 290 (68.4 [63.8–72.6]) 162 (38.2 [33.7–42.9])
 Laduani 191 (24.8) 159 (83.2 [77.3–87.9]) 70 (36.7 [30.1–43.7])
 Kwamalasamutu 155 (20.1) 77 (49.7 [41.9–57.5]) 38 (24.5 [18.4–31.9])
Sex  
 Male 314 (40.8) 219 (69.7 [64.5–74.6]) 106 (33.8 [28.8–39.2])
 Female 455 (59.1) 311 (68.4 [63.9–72.5]) 164 (36.0 [31.8–40.6])
 Unknown 1 (0.1) 0 0
Age  
 18–31 203 (26.4) 132 (65.0 [58.2–71.3]) 74 (36.5 [30.1–43.3])
 32–45 188 (24.4) 123 (65.4 [58.4–71.6]) 55 (29.3 [23.2–36.1])
 46–59 210 (27.3) 149 (71.0 [64.5–76.7]) 71 (33.8 [27.8–40.5])
 ≥60 169 (21.9) 126 (74.6 [67.5–80.5]) 70 (41.4 [34.3–49.0])
YFV vaccination status (Paramaribo only)  
 Vaccinated 166 (39.2) 114 (68.7 [61.3–75.2]) 69 (41.6 [34.3–49.2])
 Not vaccinated 114 (26.9) 84 (73.7 [64.9–80.9]) 41 (36.0 [27.7–45.1])
 Unknown 144 (33.9) 96 (66.7 [58.6–73.8]) 52 (36.1 [28.7–44.2])
Experienced ZIKV-related symptoms the past 2 years (Paramaribo only)
 One or more symptoms reported 159 (37.5) 111 (69.8 [62.3–76.4]) 55 (34.6 [27.6–42.3])
 No symptoms reported 265 (62.5) 183 (69.1 [63.3–74.3]) 107 (40.4 [34.6–46.4])
Pre-ZIKV cohort
 Total cohort 44 (100) 23 (52.3 [37.9–66.2]) 0
2000
400
352
320
288
224
192
160
128
96
64
32
0
256
Z
IK
V
 V
N
T
 ti
te
r
Pa
ra
ma
rib
o
Kw
am
ala
sam
utu
La
du
an
i
Pr
e-Z
IK
V
Cuto
Figure 1. Distribution of all individual titers from Zika virus (ZIKV) neutraliza-
tion test from the different locations of sampling. The cutoff line for a positive 
test is displayed at a reciprocal titer of 32; sera with titers above this cutoff 
were considered positive. Abbreviations: VNT, virus neutralization test; ZIKV, 
Zika virus.
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samples tested positive. Due to the low specificity the ZIKV 
IgG ELISA (47.7%) found in this study, this higher number of 
positive tests with the ZIKV IgG ELISA most likely indicates 
false-positive results due to cross-reactivity with other flavivirus 
antibodies, notably against DENV. A low specificity of the ZIKV 
IgG ELISA used in this study was recently also reported in a 
study testing a pre-ZIKV cohort from Martinique that found a 
specificity of 62.7% [9].
All of the 44 pre-ZIKV cohort samples from Suriname tested 
negative on the ZIKV VNT, which indicates that false-positive 
results due to cross-neutralization by, for example, DENV IgG, 
of which 88.6% of the pre-ZIKV cohort samples tested pos-
itive with DENV IgG ELISA, are not common with this test. 
However, it has been demonstrated that in some samples from 
secondary DENV–infected individuals, cross-neutralization of 
ZIKV can occur, mainly in samples collected during the acute 
and early convalescent phases of DENV infection [11, 14].
False-negative results of the ZIKV VNT, on the other hand, 
due to waning of neutralizing antibodies below the cutoff titer 
that was based on samples from patients with a recent ZIKV 
infection, could also be possible. This would create an under-
estimation of the real seroprevalence of ZIKV. An indication 
for this is that the VNT titers of the participants in this study 
are relatively low and are somewhat clustered around the cutoff 
titer as is illustrated in Figure 1.
In conclusion, the ZIKV seroprevalence found in this study is 
in line with previously performed ZIKV seroprevalence studies 
in the Americas and indicates that a significant amount of this 
population can still be infected with ZIKV [8–10, 12]. The 
results of this study can be useful for risk estimations of new 
ZIKV outbreaks in urban and rural areas in the Americas and 
for future ZIKV vaccine implementation in these regions.
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